Current Management of Allergic Rhinitis

被引:7
|
作者
Klimek, Ludger [1 ,7 ]
Mullol, Joaquim [2 ]
Ellis, Anne K. [3 ,4 ]
Izquierdo-Dominguez, Adrianae [5 ]
Hagemann, Jan [1 ]
Casper, Ingrid [1 ]
Davis, Abbie [3 ,4 ]
Becker, Sven [6 ]
机构
[1] Ctr Rhinol & Allergol, Quellen 10, D-65183 Wiesbaden, Germany
[2] Univ Barcelona, Hosp Clin Barcelona, Dept Otorhinolaryngol, FRCB IDIBAPS,CIBERES, Barcelona, Catalonia, Spain
[3] Queens Univ Kingston, Dept Med, Kingston, ON, Canada
[4] Queens Univ Kingston, Dept Biomed & Mol Sci, Kingston, ON, Canada
[5] Consorci Sanitari Terrassa, Dept Allergol, Barcelona, Catalonia, Spain
[6] Univ Tubingen, Dept Otorhinolaryngol Head & Neck Surg, Tubingen, Germany
[7] Ctr Rhinol & Allergol, Quellen 10, D-65183 Wiesbaden, Germany
关键词
AR treatment; Pharmacotherapy of AR; Allergen immunotherapy; Precision medicine; NASAL PROVOCATION TEST; SUBLINGUAL IMMUNOTHERAPY; INTRANASAL CORTICOSTEROIDS; SAFETY; IMPACT; EFFICACY; PREGNANCY; ASTHMA; ADOLESCENTS; CHILDREN;
D O I
10.1016/j.jaip.2024.03.023
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Allergic rhinitis (AR) is the most common allergic disease worldwide and one of the most common chronic diseases in general. Allergic rhinitis is caused by inhalant allergens from outdoor and indoor environments with varying signi fi cance of different allergens in global regions. We provide options for the current management for AR including pharmacological treatments and nonpharmacological options and allergen immunotherapy (AIT). A literature review has been conducted in Medline, Pubmed, as well as the national and international study (ClinicalTrials.gov) and guideline registers and the Cochrane Library. Human studies published on the topic in the period up to and including November 2023 were taken into account. Allergen avoidance measures, pharmacotherapy, and AIT are the cornerstones of AR treatment. Nonpharmacological measures and behavioral recommendations should be adequately added. Tools of precision medicine are already playing a signi fi cant role and will be part of the diagnostic and therapeutic standard in the future. Patients bene fi t most in a network of different pharmacological and nonpharmacological treatment measures including AIT. Application of precision medicine tools for diagnosis and treatment will improve standards of care. (c) 2024 American Academy of Allergy, Asthma & Immunology
引用
收藏
页码:1399 / 1412
页数:14
相关论文
共 50 条
  • [41] Recommendations for the pharmacologic management of allergic rhinitis
    Hoyte, Flavia C. L.
    Meltzer, Eli O.
    Ostrom, Nancy K.
    Nelson, Harold S.
    Bensch, Greg W.
    Spangler, Dennis L.
    Storms, William W.
    Weinstein, Steven F.
    Katial, Rohit K.
    ALLERGY AND ASTHMA PROCEEDINGS, 2014, 35 (03) : S20 - S27
  • [42] PROGRESS IN THE DRUG MANAGEMENT OF ALLERGIC RHINITIS
    MYGIND, N
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 1995, 252 : S68 - S72
  • [43] Latest developments in the management of allergic rhinitis
    Sanico, AM
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2004, 27 (03) : 181 - 189
  • [44] Antihistamines and the management of allergic rhinitis in the workplace
    Berman, BA
    Ross, RN
    ADVANCES IN THERAPY, 1996, 13 (02) : 95 - 102
  • [45] Management of allergic rhinitis - Antihistamines and decongestants
    Gentile, DA
    Friday, GA
    Skoner, DP
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2000, 20 (02) : 355 - +
  • [46] Allergic rhinitis - Practical management strategies
    Hu, Wendy
    Katelaris, Constance H.
    Kemp, Andrew S.
    AUSTRALIAN FAMILY PHYSICIAN, 2008, 37 (04) : 214 - +
  • [47] Pharmacological Management of Allergic Rhinitis in the Elderly
    Andrzej Bozek
    Drugs & Aging, 2017, 34 : 21 - 28
  • [48] MANAGEMENT OF ALLERGIC RHINITIS IN GENERAL PRACTICE
    FREED, DLJ
    PRACTITIONER, 1976, 216 (1293) : 330 - 333
  • [49] A review of the current guidelines for allergic rhinitis and asthma
    Lemanske, RF
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (02) : S392 - S396
  • [50] Allergic rhinitis: An assessment of current pharmacotherapeutic options
    Galant, SP
    Wilkinson, R
    FORMULARY, 1999, 34 (12) : 1016 - +